# Crescent Biopharma Advances Clinical Pipeline and Sets 2027 Data Timelines

- URL: https://stocks.freetheai.org/news/crescent-biopharma-advances-clinical-pipeline-and-sets-2027-data-timelines-ff653b
- Published: 2026-10-15T20:33:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:CBIO](https://stocks.freetheai.org/symbols/NASDAQ-CBIO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Crescent Biopharma, Inc. (CBIO) has opened patient enrollment for drug combination trials testing CR-001 with chemotherapy across several tumor types. The company also secured authorization from the U.S. Food and Drug Administration for an Investigational New Drug application for CR-002, an antibody-drug conjugate targeting PD-L1.

The updates signal progress across the biotech firm's oncology pipeline as it transitions treatments into advanced early-stage human testing. Crescent Biopharma completed dose escalation in its ASCEND Phase 1/2 trial for CR-001 monotherapy, preparing the ground for broader evaluation. In addition, its collaboration with Kelun-Biotech includes active combination trials in China and exclusive rights to CR-003 outside Greater China.

Investors can expect several data readouts starting in early 2027. Monotherapy results from over 125 patients in the ASCEND trial and preliminary proof-of-concept data for CR-003 are both slated for the first quarter of 2027. Initial combination study data for CR-001 is expected in mid-2027, while the global APOLLO Phase 1/2 trial for CR-002 is set to begin in the fourth quarter of 2026, with initial results arriving in the second half of 2027.

## Key points

- Crescent Biopharma completed CR-001 monotherapy dose escalation and started chemo combination cohorts across several tumor types.
- The FDA cleared the Investigational New Drug application for CR-002, allowing the global Phase 1/2 APOLLO trial to begin in Q4 2026.
- Initial trial data for CR-001 monotherapy and proof-of-concept results for CR-003 are expected in the first quarter of 2027.
- Combination study results for CR-001 are anticipated in mid-2027, followed by initial CR-002 data in the second half of 2027.

## Questions and answers

### What clinical updates did Crescent Biopharma announce?

Crescent Biopharma started enrollment in CR-001 chemotherapy combination trials, gained FDA clearance to begin Phase 1/2 trials for CR-002, and outlined trial readout goals spanning through 2027.

### When will Crescent Biopharma report CR-001 trial data?

Initial CR-001 monotherapy data from over 125 patients is planned for the first quarter of 2027, with chemo combination study results expected in mid-2027.

### What is the timeline for Crescent Biopharma's CR-002 trial?

Following FDA IND clearance, Crescent Biopharma plans to launch the global Phase 1/2 APOLLO trial for CR-002 in the fourth quarter of 2026, with initial trial data expected in the second half of 2027.